Appili Therapeutics: a David taking on the COVID-19 Goliath BNN published an article this morning about Appili Therapeutics. The article atalks about the company's goal to fight against infectious diseases with a mission to find solutions against life-threatening infections.
It's therefore reassuring that flying under the radar is Halifax-headquartered Appili Therapeutics Inc. (TSX: APLI | OTCQX: APLIF), a biopharmaceutical company that has quietly built a portfolio of projects that have put it at the forefront of the global fight against infectious diseases.
The company was built to take on those human pathogens and help develop solutions to these life-threatening infections.
Appili’s lead program is an oral antiviral for the treatment of COVID-19. As part of a global consortium, the company is conducting a large international phase 3 clinical trial (PRESECO) evaluating the antiviral Favipiravir for the treatment of mild/moderate COVID-19 in subjects not yet hospitalized.
Read the full article here.
Find out more about Appili here.